Timing of Genmab’s Daratumumab Presentations at EHA Congress
6/14/2012 1:39 AM EST
Genmab A/S
Investor News
Timing of Genmab’s Daratumumab Presentations at EHA Congress
Media Release
-- Oral presentation to take place June 17 10.45-11am CEST in the Main
Auditorium at the EHA congress in Amsterdam
-- New Pharmacokinetics (PK) data presented
-- Three additional daratumumab presentations
Copenhagen, Denmark; June 14 2012 – Genmab A/S (OMX: GEN) announced today the
timing of the oral presentation of preliminary data from the ongoing
daratumumab Phase I/II study in multiple myeloma at the 17th Congress of the
European Hematology Association (EHA) in Amsterdam, June 14-17 2012.
The presentation details are as follows:
Title: Daratumumab, A CD38 monoclonal antibody in patients with multiple
myeloma – Preliminary efficacy and pharmacokinetics data from a dose-escalation
phase I/II study
Date: Sunday June 17 2012
Time: 10.45-11am CEST
Presenter: Dr. Henk Lokhorst, University Medical Center Utrecht, Utrecht, The
Netherlands
The abstract is available on the EHA website:
https://www.eventure-online.com/eventure/publicAbstractView.do?id=193081&congres
sId=5650
Slides from the presentation will be made available on Genmab’s homepage after
the presentation, at the following link www.genmab.com
The oral presentation covers preliminary safety and efficacy data from the
ongoing Phase I/II study and includes new pharmacokinetics (PK) data which
shows how the antibody is absorbed and distributed in the body of patients. The
PK data showed that at therapeutic dose levels a higher degree of responses
were seen, with most patients exhibiting a significant reduction in key disease
biomarker levels (which include serum M-component, urine M-component and serum
free light chains, measured according to the International Myeloma Working
Group (IMWG) guidelines) showing that the antibody is clinically active in
heavily pre-treated multiple myeloma patients.
In addition, daratumumab data will be highlighted today at 5.25pm CEST in the
satellite symposium, entitled “Achieving and maintaining disease control in
multiple myeloma”, in a presentation by Dr. Xavier Leleu, entitled ‘Future
therapeutic options on the horizon for multiple myeloma’, and in two further
daratumumab poster presentations at EHA.
Poster presentations
June 15, 2012 at 5.45-7pm CEST: Reconstructing the Human Hematopoietic Niche:
Opportunities for Studying Normal and Malignant Hematopoiesis.
Abstract:
https://www.eventure-online.com/eventure/publicAbstractView.do?id=194581&congres
sId=5650
June 16 5.45-7pm CEST: Towards Personalized medicine using a novel preclinical
model: Identifying daratumumab as effective treatment for Multiple Myeloma.
Abstract:
https://www.eventure-online.com/eventure/publicAbstractView.do?id=194208&congres
sId=5650
See the EHA website for further details on the Congress www.ehaweb.org
About daratumumab
Daratumumab, a human CD38 monoclonal antibody with broad-spectrum killing
activity, is in clinical development for multiple myeloma. The CD38 molecule is
highly expressed on the surface of multiple myeloma cells. Daratumumab could
also have potential in other hematological tumors on which CD38 is expressed,
including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute
lymphoblastic leukemia, acute myeloid leukemia, follicular lymphoma and mantle
cell lymphoma.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company’s first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab’s validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab’s strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E:
This Media Release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with pre-clinical and
clinical development of products, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Media Release nor to confirm such
statements in relation to actual results, unless required by law.
Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax®-EGFr;
HuMax®-IL8; HuMax®-TAC; HuMax®-CD38; HuMax®-TF; HuMax®-TF-ADC; HuMax®-Her2;
HuMax®-cMet, HuMax®-CD74, DuoBody™ and UniBody® are all trademarks of Genmab
A/S. Arzerra® is a trademark of GlaxoSmithKline.
Media Release no. 04
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark